Respiratory Health in Focus: Pulmonary Tuberculosis Research and Management

Paul Wbleman^*
*Correspondence: Paul Wbleman, Department of Pulmonary, Critical Care and Sleep Medicine, Stony Brook University, New York, USA, Email:

Introduction

Respiratory health is a critical aspect of overall well-being, as the lungs play a central role in maintaining the body's oxygen supply and removing waste gases. Among the myriad respiratory diseases, pulmonary Tuberculosis (TB) stands out as one of the most significant public health challenges worldwide. This article delves into the intricacies of pulmonary tuberculosis research and management, exploring the history of the disease, its current status, diagnostic techniques, treatment options, and future prospects for tackling this global menace. To understand the present state of pulmonary tuberculosis research and management, it is crucial to delve into the historical context of the disease. TB has plagued humanity for centuries, with evidence of infection dating back to ancient times. Known as the "White Plague," TB has been responsible for a considerable share of human suffering and death throughout history.

Description

The first documented evidence of TB dates back to ancient Egypt, where mummies with signs of the disease have been found. Similarly, ancient Greece and Rome reference a disease that resembles TB in their medical texts. The 19th century saw a major outbreak of TB, often referred to as the tuberculosis pandemic. During this period, TB claimed countless lives, and its prevalence skyrocketed, particularly in urban areas with overcrowded living conditions. The late 19th and early 20th centuries brought significant scientific discoveries regarding the etiology and transmission of TB. Robert Koch's discovery of the tubercle bacillus (Mycobacterium tuberculosis) in 1882 marked a turning point in the understanding of the disease. This discovery led to improved diagnostic tools and laid the foundation for TB research and management [1].

Despite the advances in knowledge and treatment, TB remains a global health challenge. The World Health Organization (WHO) classifies TB as one of the top ten causes of death worldwide. Here, we will delve into the current status of TB, its prevalence, risk factors, and impact on global health.

TB is a leading cause of mortality worldwide. In 2020, there were an estimated 10 million new cases of TB, and 1.5 million deaths attributed to the disease, with over 95% of these deaths occurring in low- and middle-income countries. Individuals with compromised immune systems, such as those living with HIV, malnutrition, or other chronic illnesses, are more susceptible to TB. TB is highly contagious and spreads through the air when an infected person coughs or sneezes. Close and prolonged contact with an infected individual increases the risk of transmission. Sputum smear microscopy, a traditional diagnostic technique, involves examining sputum samples under a microscope to detect the presence of Acid-Fast Bacilli (AFB). While it is a cost-effective and widely available method, its sensitivity is relatively low, particularly in cases of paucibacillary TB [2].

Chest X-rays are used to identify lung abnormalities consistent with TB. While they can provide important diagnostic information, they are not definitive and may require further tests for confirmation.

NAATs, including the Polymerase Chain Reaction (PCR), detect the genetic material of M. tuberculosis in sputum samples. These tests offer greater sensitivity and specificity than sputum smear microscopy, making them valuable in diagnosing TB, especially in cases of extra pulmonary and drug-resistant TB.

IGRAs are blood tests that assess the body's immune response to TB-specific antigens. These tests are particularly useful in detecting Latent TB Infection (LTBI) and are less affected by BCG vaccination status, which can sometimes lead to false-positive results in tuberculin skin tests. Tuberculin skin tests involve injecting a small amount of TB antigen (tuberculin) under the skin and assessing the immune response. While TSTs have been used for decades, they have limitations, such as false-positive results due to previous BCG vaccination or exposure to non-tuberculous mycobacteria. Advancements in molecular biology and genomics have allowed for the development of novel diagnostic techniques. These approaches, such as whole-genome sequencing, enable a deeper understanding of TB strains, their drug resistance profiles, and transmission patterns. The treatment and management of pulmonary tuberculosis have evolved significantly over the years, with the introduction of anti-tubercular drugs and directly observed therapy. Effective TB management requires a combination of drug therapy, patient support, and public health measures. The cornerstone of TB treatment is a combination of anti-tubercular drugs. The standard regimen for drug-sensitive TB typically involves a combination of four first-line drugs: isoniazid, rifampicin, pyrazinamide, and ethambutol. The treatment course typically lasts for six months, but it may be extended in some cases. Directly observed therapy is a strategy that ensures patients take their medications as prescribed. A healthcare worker or trained observer directly observes the patient taking their TB medications, which helps improve adherence and reduce the risk of drug resistance. Multidrug-resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) pose significant challenges in TB management. Treating these forms of TB requires more prolonged and complex drug regimens, often with less effective and more toxic drugs. Newer drugs, such as bedaquiline and delamanid, have been developed to treat drug-resistant TB and offer hope for more effective management.

The emergence of antibiotic resistance has prompted a shift towards antimicrobial stewardship in VAP management. This involves a more judicious use of antibiotics to prevent the development of further resistance. Antimicrobial stewardship programs help guide clinicians in selecting appropriate antibiotics based on local resistance patterns, patient risk factors, and culture results. Immunomodulatory therapies are being explored as adjunctive treatments for VAP. These therapies aim to modulate the patient's immune response and reduce inflammation, which plays a significant role in the pathogenesis of VAP. Research into therapies like monoclonal antibodies and cytokine inhibitors holds promise in improving patient outcomes [3].

Preventing VAP remains a primary goal, and recent trends focus on innovative strategies to reduce the risk of infection. One approach involves the use of probiotics or beneficial bacteria to promote a healthy lung microbiome and compete with pathogenic organisms. This tactic, though still under investigation, holds potential for preventing VAP by maintaining a balanced microbial environment. The utilization of advanced technologies like closed-loop mechanical ventilation systems has gained traction. These systems incorporate real-time data to adjust ventilator settings and prevent lung over distension, a common risk factor for VAP. By tailoring ventilation to individual patient needs, these systems aim to reduce the likelihood of developing pneumonia. A notable trend is the shift towards patient-centred care in VAP management. As healthcare evolves, there is an increasing emphasis on shared decision-making between patients, families, and healthcare providers. This approach takes into account patient preferences, values, and goals when making treatment decisions, ultimately leading to more personalized and effective care. Telemedicine has also become a crucial component of patient-centred care, especially in the context of post-ICU follow-up. Patients who have survived critical illness, including VAP, often experience long-term physical and psychological effects. Telemedicine enables remote monitoring and virtual consultations, providing ongoing support to patients as they recover [4].

The challenges posed by VAP are not limited to high-income countries; they also affect low- and middle-income countries with limited resources. Addressing VAP on a global scale involves adapting diagnostic and management strategies to suit the available resources and infrastructure. Initiatives such as training healthcare workers, implementing basic infection control measures, and promoting antibiotic stewardship are critical in reducing the burden of VAP in resource-constrained settings [5].

Conclusion

Respiratory health remains a paramount concern in global healthcare, with pulmonary Tuberculosis (TB) standing out as one of the most challenging and persistent diseases in this domain. The historical backdrop of TB reminds us of its enduring presence throughout human history, even as science has brought us closer to understanding and managing this disease. Despite significant progress, TB continues to exert a substantial toll on public health, especially in low- and middle-income countries. The current status of TB is a stark reminder that this ancient pathogen remains a formidable foe. With millions of new cases and hundreds of thousands of deaths each year, TB remains a global public health crisis. Risk factors such as weakened immune systems, close contact, and drug resistance contribute to the perpetuation of this disease, making it a challenge that transcends borders and socioeconomic disparities. Efforts to diagnose TB have come a long way from the early days of sputum smear microscopy. Modern diagnostic tools, including nucleic acid amplification tests, interferon-gamma release assays, and molecular and genomic approaches, have improved our ability to detect TB with greater accuracy. However, there is still a need for more accessible and affordable diagnostic methods, especially in resource-limited settings.

Acknowledgement

None.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

1. Card, Jeffrey W., Darryl C. Zeldin, James C. Bonner and Earle R. Nestmann. "Pulmonary applications and toxicity of engineered nanoparticles." Am J Physiol Lung Cell Mol Physiol 295 (2008): L400-L411.

Google Scholar, Crossref, Indexed at

2. Rozali, Esdy N., Stanleyson V. Hato, Bruce W. Robinson and Richard A. Lake, et al. "Programmed death ligand 2 in cancer-induced immune suppression." Clin Dev Immunol 2012 (2012).

Google Scholar, Crossref, Indexed at

3. Xu, Dongbo, Min Ma, Zixin Deng and Kui Hong. "PreQ0 base, an unusual metabolite with anti-cancer activity from Streptomyces qinglanensis 172205." Anticancer Agents Med Chem 15 (2015): 285-290.

Google Scholar, Crossref, Indexed at

4. Verma, Vijay C., Ravindra N. Kharwar and Gary A. Strobel. "Chemical and functional diversity of natural products from plant associated endophytic fungi." Nat Prod Commun 4 (2009): 1934578X0900401114.

Google Scholar, Crossref

5. Garcia-Diaz, Angel, Daniel Sanghoon Shin, Blanca Homet Moreno and Justin Saco, et al. "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression." Cell Rep 19 (2017): 1189-1201.

Google Scholar, Crossref, Indexed at